pyrroles has been researched along with Chronic Kidney Diseases in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (84.62) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Gao, X; Han, Y; Hao, J; Liang, L; Qiang, P; Shimosawa, T; Xian, Y; Xiong, Y; Xu, Q; Yang, F | 1 |
| Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A | 1 |
| Chen, HY; Chen, J; Diamantidis, CJ; Doerfler, RM; Fink, JC; Rahman, M; Ricardo, AC; Sondheimer, J; Strauss, L; Wagner, LA; Weir, MR; Xie, D; Zhan, M | 1 |
| Nishiyama, A; Rahman, A; Wan, N | 1 |
| Knap, N; Lizakowski, S; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M | 1 |
| Cooley, C; Dobberfuhl, AD; Goldschmeding, R; Higgins, PJ; Meldrum, KK; Overstreet, JM; Patel, S; Samarakoon, R | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Cohen, DJ; Cooper, CJ; Cutlip, DE; D'Agostino, RB; Dworkin, LD; Henrich, W; Jaff, MR; Jamerson, K; Lewis, EF; Massaro, JM; Matsumoto, AH; Murphy, TP; Prince, MR; Reid, DM; Rundback, JH; Shapiro, JI; Steffes, M; Tuttle, KR | 1 |
| Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB | 2 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Coombes, JS; Fassett, RG; Geraghty, DP | 1 |
| Campese, VM | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Chngrian, GV; Mysyshin, MB; Salomenchuk, TN; Semegen-Bodak, KV; Slaba, nA; Slabyĭ, OM | 1 |
| Chen, JY; Chen, PY; Duan, CY; Li, HL; Li, LW; Liu, Y; Liu, YH; Luo, JF; Tan, N; Zhou, YL | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Manzone, C; Micheletti, C; Tedeschi, D; Toso, A | 1 |
| Aleksandrowicz, E; Larczyński, W; Lysiak-Szydłowska, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Ziętkiewicz, M | 1 |
| Baigorria, ST; Eynard, AR; Fiore, MC; García, NH; Juncos, LA; Juncos, LI; Martín, FL; Pasqualini, ME | 1 |
| Babazono, T; Fujimoto, A; Imamoto, M; Kasahara, M; Kimura, G; Koya, D; Nakao, K; Sato, T; Tanaka, S; Ueshima, K; Yasuno, S | 1 |
| Allolio, B; Bidlingmaier, M; Blouin, K; Drechsler, C; Fassnacht, M; Hammer, F; Krane, V; März, W; Pilz, S; Ritz, E; Schönfeld, S; Tomaschitz, A; Wanner, C | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
4 review(s) available for pyrroles and Chronic Kidney Diseases
| Article | Year |
|---|---|
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Pyrroles; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone; Sulfones | 2021 |
Do statins play a role in renoprotection?
Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
11 trial(s) available for pyrroles and Chronic Kidney Diseases
| Article | Year |
|---|---|
[Isoprostanes - important marker of the oxidative stress estimation in patients with chronic kidney disease].
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Isoprostanes; Male; Middle Aged; Oxidative Stress; Protective Agents; Pyrroles; Renal Insufficiency, Chronic; Renin-Angiotensin System; Young Adult | 2013 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Stenting and medical therapy for atherosclerotic renal-artery stenosis.
Topics: Aged; Amlodipine; Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Renal Artery; Renal Artery Obstruction; Renal Insufficiency, Chronic; Stents; Treatment Failure | 2014 |
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins | 2014 |
Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Renal Insufficiency, Chronic; Tasmania; Time Factors; Treatment Outcome | 2014 |
Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Epithelial Sodium Channels; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Renal Insufficiency, Chronic; Vascular Stiffness | 2014 |
[Antiatherogenic and nephroprotective efficacy of atorvastatin in patients with chronic renal disease of non-diabetic origin].
Topics: Anticholesteremic Agents; Atorvastatin; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Kidney Function Tests; Lipid Metabolism; Male; Middle Aged; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Topics: Aged; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Creatinine; Female; Fluid Therapy; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Risk Factors | 2010 |
Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Topics: Adult; Atorvastatin; Cross-Over Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Pyrroles; Renal Insufficiency, Chronic | 2010 |
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Data Interpretation, Statistical; Disease Progression; Dyslipidemias; Endpoint Determination; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Research Design; Treatment Outcome | 2013 |
11 other study(ies) available for pyrroles and Chronic Kidney Diseases
| Article | Year |
|---|---|
Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone.
Topics: Aldosterone; Animals; Eplerenone; Fibrosis; Macrophages; Mice; Myofibroblasts; Pyrroles; Rats; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Sulfones; Transforming Growth Factor beta1 | 2022 |
Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.
Topics: Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2023 |
Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Black or African American; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Pain; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Quality of Life; Renal Insufficiency, Chronic; Renal Replacement Therapy; White People; Young Adult | 2020 |
Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species.
Topics: Animals; Benzothiazoles; Connective Tissue Growth Factor; Endothelium, Vascular; ErbB Receptors; Fibroblasts; Fibrosis; Gene Expression Regulation; Isoquinolines; Mice; Mink; Myocytes, Smooth Muscle; Pyridines; Pyrroles; Quinazolines; Rats; Reactive Oxygen Species; Renal Insufficiency, Chronic; Serpin E2; Signal Transduction; Smad2 Protein; Smad3 Protein; Toluene; Transforming Growth Factor beta1; Tumor Suppressor Protein p53; Tyrphostins | 2013 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
The impact of pre-intervention rate of kidney function change on the assessment of CKD progression.
Topics: Aged; Atorvastatin; Biomarkers; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Recovery of Function; Renal Insufficiency, Chronic; Research Design; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Topics: Animals; Atorvastatin; Blood Pressure; Creatinine; Diet; Fatty Acids, Unsaturated; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Male; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium Chloride, Dietary | 2012 |
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Anticholesteremic Agents; Atorvastatin; Death, Sudden, Cardiac; Drug Synergism; Female; Heptanoic Acids; Humans; Hydrocortisone; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Young Adult | 2013 |